|
1
|
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.
|
J Pathol
|
2010
|
2.27
|
|
2
|
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
|
J Clin Oncol
|
2009
|
2.13
|
|
3
|
Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
|
J Clin Oncol
|
2013
|
1.17
|
|
4
|
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.
|
BMC Cancer
|
2010
|
1.14
|
|
5
|
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.
|
Blood
|
2012
|
1.06
|
|
6
|
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
|
Eur J Cancer
|
2013
|
1.02
|
|
7
|
Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy.
|
J Hematol Oncol
|
2011
|
0.98
|
|
8
|
Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party.
|
Int J Hematol
|
2010
|
0.96
|
|
9
|
Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
|
Int J Cancer
|
2011
|
0.93
|
|
10
|
Plerixafor use for peripheral blood stem cell mobilization in Korea.
|
Blood Res
|
2013
|
0.86
|
|
11
|
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
|
Ann Hematol
|
2013
|
0.86
|
|
12
|
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
|
Ann Hematol
|
2011
|
0.86
|
|
13
|
Absence of IDH2 codon 172 mutation in common human cancers.
|
Int J Cancer
|
2009
|
0.85
|
|
14
|
Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma.
|
Cancer Chemother Pharmacol
|
2013
|
0.85
|
|
15
|
Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
|
Cancer Sci
|
2010
|
0.81
|
|
16
|
Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report.
|
Leuk Res
|
2010
|
0.80
|
|
17
|
Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias.
|
Leuk Res
|
2010
|
0.80
|
|
18
|
Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.
|
Ann Hematol
|
2014
|
0.80
|
|
19
|
Consideration of aggressive therapeutic strategies for primary testicular lymphoma.
|
Am J Hematol
|
2007
|
0.79
|
|
20
|
Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study.
|
Int J Hematol
|
2010
|
0.78
|
|
21
|
A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
|
Cancer Chemother Pharmacol
|
2008
|
0.78
|
|
22
|
Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature.
|
Korean J Lab Med
|
2010
|
0.78
|
|
23
|
Somatic mutation of PIK3R1 gene is rare in common human cancers.
|
Acta Oncol
|
2010
|
0.77
|
|
24
|
Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
|
Invest New Drugs
|
2009
|
0.77
|
|
25
|
Somatic mutation of GNAQ gene is rare in common solid cancers and leukemias.
|
Acta Oncol
|
2009
|
0.76
|
|
26
|
Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas.
|
Acta Oncol
|
2009
|
0.76
|
|
27
|
Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers.
|
APMIS
|
2010
|
0.75
|
|
28
|
Analysis of NOTCH1 extracellular juxtamembrane expansion mutations in acute leukemias and multiple myelomas.
|
APMIS
|
2009
|
0.75
|
|
29
|
Comparable analysis of outcomes for allogeneic peripheral blood stem cell transplantation from matched related and matched unrelated donors in acute myeloid leukemia.
|
Acta Haematol
|
2011
|
0.75
|
|
30
|
Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors.
|
Ann Hematol
|
2010
|
0.75
|
|
31
|
Mutational analysis of UBR5 gene encoding an E3 ubiquitin ligase in common human cancers.
|
Pathology
|
2010
|
0.75
|